

6MWT: Change from baseline by visit
ITT population
Page 4 of 4

	Placebo to Natalizumab 300 mg	Natalizumab 300 mg	p-value (a)
Change from Baseline to Week 156			
n	272	289	
Mean	-32.1	-40.4	0.8066
SD	117.55	219.60	

(a)p-value for comparison between the active and placebo groups at Week 156 is based on ANCOVA model, adjusted for DSS (≤ 5.5 or ≥ 6) and baseline 6MWT.